Application of a low-temperature plasma-activated solution in the in vitro inhibition of inflammatory responses in boar testicular Sertoli cells
By treating boar testicular support cells with low-temperature plasma activation solution and optimizing parameters to suppress inflammatory responses, this method solves the problems of high cytotoxicity and poor adaptability in existing technologies, providing a safe and efficient in vitro anti-inflammatory solution that meets the needs of boar reproductive inflammation research.
Patent Information
- Application Number
- CN202611570666.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-12
- Publication Date
- 2026-11-10
AI Technical Summary
Existing boar testicular supporting cell inflammation intervention techniques suffer from high cytotoxicity, unclear efficacy, poor adaptability, and a lack of standardized and safe in vitro anti-inflammatory treatment methods, making it difficult to meet the needs of research on the reproductive inflammation mechanism of boars and the screening of anti-inflammatory drugs.
Low-temperature plasma activation solution (PAM) was used to treat serum-containing cell culture medium through dielectric barrier discharge to prepare a solution for in vitro inhibition of inflammatory responses in boar testicular Sertoli cells. The treatment parameters were optimized to maintain cell viability and reduce the expression of inflammatory factors.
This approach achieves low-toxicity, standardized in vitro anti-inflammatory intervention, significantly reduces the expression of inflammatory factors, and provides an effective research tool and protective measure.
Smart Images

Figure CN123063340A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of animal cell in vitro culture and cell inflammation regulation technology, specifically relating to the application of a low-temperature plasma activation solution in inhibiting the inflammatory response of boar testicular supporting cells in vitro. Background Technology
[0002] Sertoli cells (SCs) in boars play a central regulatory role in spermatogenesis, and their functional state directly determines semen quality and boar reproductive performance. my country is the world's largest pig-producing country, and the pig industry holds a vital strategic position in the national economy and people's livelihood. Boar reproductive performance is a key factor affecting the genetic progress of pig herds and the efficiency of large-scale production. Sertoli cells provide structural support and nutrient supply to spermatogenic cells and maintain the stability of the testicular microenvironment by constructing the blood-testis barrier. Various factors, such as environmental toxins, heat stress, and pathogenic microbial infections, can induce inflammatory responses in Sertoli cells. Inflammatory factors can damage the blood-testis barrier, induce spermatogenic cell apoptosis, and cause a decline in semen quality, which in severe cases can render the boar unusable for breeding.
[0003] Current in vitro intervention methods for treating Sertoli cell inflammation in the testes still have significant shortcomings. Traditional anti-inflammatory drugs are prone to cytotoxicity, while antioxidants suffer from unclear targets and unstable efficacy. Existing low-temperature plasma-related studies mostly employ direct irradiation, which easily induces Sertoli cell apoptosis and is unsuitable for suppressing inflammation while preserving cell viability. A few plasma activation solutions are primarily used for in vivo tissue inflammation treatment, and their systems are incompatible with the in vitro culture environment of boar testicular Sertoli cells, making them unsuitable for direct anti-inflammatory intervention at the cellular level. Furthermore, existing research on boar testicular Sertoli cells largely focuses on elucidating the mechanisms of inflammation, lacking standardized, safe, and efficient in vitro anti-inflammatory treatment methods, which fails to meet the research needs for studying inflammation mechanisms and screening anti-inflammatory drugs.
[0004] Plasma-Activated Medium (PAM) is a liquid medium prepared by low-temperature plasma discharge treatment. Rich in reactive oxygen species and nitrogen species, it offers advantages such as safety, controllability, ease of storage, and standardized preparation. Existing research has confirmed its ability to regulate cellular inflammation-related pathways and downregulate the expression of various inflammatory factors. Currently, there are no reports on using plasma-activated medium to inhibit inflammatory responses in porcine testicular Sertoli cells. Summary of the Invention
[0005] To address the numerous shortcomings of existing boar testicular Sertoli cell (SSC) inflammation intervention techniques, this invention aims to provide an application and method for inhibiting inflammatory responses in boar testicular Sertoli cells in vitro using plasma-activated liquid. Existing traditional anti-inflammatory and antioxidant intervention methods suffer from high toxicity and unclear efficacy; conventional low-temperature plasma direct irradiation easily induces Sertoli cell apoptosis, failing to achieve anti-inflammatory regulation while maintaining cell viability; existing plasma activation liquid technology is mostly used for in vivo tissue inflammation treatment and is not suitable for in vitro culture systems of testicular Sertoli cells, thus failing to achieve precise cell-level anti-inflammatory intervention. Furthermore, the current lack of standardized, safe, and controllable in vitro inflammatory intervention tools for boar testicular Sertoli cells severely restricts research on the mechanisms of reproductive inflammation in breeding boars and the screening of anti-inflammatory strategies. Therefore, this invention utilizes the advantages of plasma activation liquid—safety, low toxicity, and standardized controllability—to establish a highly efficient in vitro treatment scheme for inhibiting boar testicular Sertoli cell inflammation, filling the technological gaps of existing technologies characterized by high cytotoxicity, poor adaptability, weak controllability, and the lack of dedicated in vitro intervention methods.
[0006] To achieve the above-mentioned technical effects, the present invention employs the following technical means:
[0007] This invention first discloses the application of a low-temperature plasma activation solution in the preparation of a product for inhibiting inflammatory responses in boar testicular Sertoli cells in vitro.
[0008] Furthermore, the low-temperature plasma activation liquid is a plasma-activated culture medium obtained by discharging a serum-containing cell culture medium with dielectric barrier discharge low-temperature plasma under an inert working gas atmosphere.
[0009] Furthermore, the inert working gas is helium, and its purity is ≥99.999%;
[0010] The serum-containing cell culture medium is DMEM / F12 medium containing 10% fetal bovine serum;
[0011] During the discharge treatment, the culture medium volume was 15 mL and placed in a 60 mm diameter petri dish. The distance between the plasma generating electrode and the liquid surface was 10 mm. The helium flow rate was 1.0 L / min. The discharge treatment was carried out 30 s after exhaust.
[0012] Furthermore, under the condition of a fixed discharge time of 10 s, the discharge voltage of the discharge treatment is 20-60V.
[0013] Furthermore, the discharge voltage of the discharge treatment is 40 V and the discharge time is 20 s.
[0014] Furthermore, the inflammatory response is a lipopolysaccharide-induced inflammatory response;
[0015] The boar testicular Sertoli cells were primary boar testicular Sertoli cells that had been treated with 50 µg / mL lipopolysaccharide for 24 h to establish an inflammation model.
[0016] Furthermore, the boar testicular supporting cells are primary cells with a purity ≥95% as identified by GATA-4 immunofluorescence; and / or the low-temperature plasma activation solution has a better or equivalent inhibitory effect on the level of inflammatory factors than N-acetylcysteine.
[0017] Furthermore, the porcine testicular supporting cells were treated with the aforementioned low-temperature plasma activation solution for 1–8 hours.
[0018] Furthermore, the porcine testicular supporting cells were treated with the aforementioned low-temperature plasma activation solution for 2 hours; and the cell viability recovered to a level not significantly different from the control group after treatment, and the level of lipopolysaccharide-induced inflammatory factors was significantly reduced.
[0019] Furthermore, the product is used to reduce at least one of interleukin-6, tumor necrosis factor-α, interleukin-1β, and interleukin-18; and / or reduce intracellular reactive oxygen species levels; and to inhibit at least one of p-IκB / IκB, p-p65 / p65, nuclear p65, and NLRP3; and / or to restore at least one of tight junction proteins ZO-1, Occludin, Claudin-3, and Claudin-11.
[0020] The beneficial effects of this invention are as follows:
[0021] 1. The process of preparing low-temperature plasma activation solution does not involve the addition of chemical reagents, leaves no chemical drug residues, has relatively low cytotoxicity, and exhibits good biocompatibility.
[0022] 2. The preparation process of the low-temperature plasma activation solution is simple, and it can be prepared and added to the cell culture system at any time without the need for special equipment.
[0023] 3. Experimental data show that the expression levels of inflammatory factors IL-1β, IL-6, IL-18 and TNF-α in testicular Sertoli cells treated with the activation solution of this invention are significantly reduced.
[0024] 4. The activation solution can be prepared in a standardized manner by adjusting the plasma treatment parameters, which facilitates its widespread application.
[0025] 5. This invention provides an effective intervention tool for in vitro research on the inflammatory mechanism of testicular Sertoli cells, and also provides a technical basis for the development of Sertoli cell protection-related products. Attached Figure Description
[0026] Figure 1Isolation, culture, and purity identification of boar testicular Sertoli cells: A shows isolated and cultured boar testicular Sertoli cells; B shows the purity of the testicular Sertoli cells identified by immunofluorescence labeling with GATA-4.
[0027] Figure 2 A testicular Sertoli cell inflammation model was constructed using lipopolysaccharide (LPS): A) Sertoli cell viability was measured using CCK-8 assay at different LPS concentrations; B) IL-6 levels in Sertoli cells were measured using ELISA at different LPS concentrations; C) Protein levels of IL-1β and IL-18 in Sertoli cells were detected using Western blotting at different LPS concentrations.
[0028] Figure 3 Effects of PAM prepared by dielectric barrier discharge at different voltages for 10 s on LPS-induced viability and inflammatory factors in testicular Sertoli cells: A shows the effect of PAM treatment at different voltages on the viability of normal Sertoli cells as determined by CCK-8 assay; B shows the effect of PAM treatment at different voltages on LPS-induced Sertoli cell viability as determined by CCK-8 assay; C shows the effect of PAM treatment at different voltages on the protein levels of TNF-α and IL-1β in LPS-induced Sertoli cells as detected by Western blotting; D shows the two-dimensional scatter plot of cell viability and relative expression levels of TNF-α and IL-1β.
[0029] Figure 4 The effects of PAM prepared under dielectric barrier discharge at 40 V for different durations on LPS-induced viability and inflammatory factors in testicular Sertoli cells: A shows the effect of PAM treatment at different discharge times on the viability of normal Sertoli cells as determined by CCK-8 assay; B shows the effect of PAM at different discharge times on LPS-induced Sertoli cell viability as determined by CCK-8 assay; C and D show the effect of PAM at different discharge times on the levels of IL-1β and IL-18 proteins in LPS-induced Sertoli cells as detected by Western blotting; E shows the two-dimensional scatter plot of cell viability and the relative expression levels of IL-1β and IL-18.
[0030] Figure 5 The effects of different PAM (40 V - 20 s) treatment times on LPS-induced testicular Sertoli cell viability and inflammatory factors: A shows the effect of different PAM treatment times on normal Sertoli cell viability as determined by CCK-8 assay; B shows the effect of different PAM treatment times on LPS-induced Sertoli cell viability as determined by CCK-8 assay; CE shows the effect of different PAM treatment times on LPS-induced Sertoli cell IL-1β and IL-18 protein levels as detected by Western Blot; F is a two-dimensional scatter plot showing the distribution of cell viability and relative expression levels of IL-1β and IL-18.
[0031] Figure 6Effects of PAM (40 V-20 s) and N-acetylcysteine (NAC) (5 mM) treatment for 2 h on LPS-induced testicular Sertoli cell viability and inflammatory factors: A: Effect of PAM and NAC on LPS-induced Sertoli cell viability as determined by CCK-8 assay; B: Effect of PAM and NAC on IL-6 levels in LPS-induced Sertoli cells as determined by ELISA; C: Effect of PAM and NAC on TNF-α levels in LPS-induced Sertoli cells as determined by ELISA; D: Effect of PAM and NAC on IL-1β levels in LPS-induced Sertoli cells as determined by ELISA; E: Effect of PAM and NAC on IL-18 protein levels in LPS-induced Sertoli cells as determined by Western Blot.
[0032] Figure 7 Effect of PAM (40 V - 20 s) treatment for 2 h on LPS-induced reactive oxygen species (ROS) levels in testicular supporting cells: results of DCFDA fluorescence staining and quantitative analysis.
[0033] Figure 8 Effects of PAM (40 V - 20 s) treatment for 2 h on LPS-induced inflammatory pathways in testicular Sertoli cells: A shows the effect of PAM on the levels of p-IκB / IκB, p-p65 / p65, and NLRP3 proteins in LPS-induced Sertoli cells detected by Western Blot; B shows the effect of PAM on the level of p65 protein in the nucleus of LPS-induced Sertoli cells detected by Western Blot.
[0034] Figure 9 Effects of PAM (40 V - 20 s) treatment for 2 h on LPS-induced tight junction proteins in testicular Sertoli cells: Western blot analysis was conducted to detect the effects of PAM on the protein levels of ZO-1, Occludin, Claudin-3, and Claudin-11 in LPS-induced Sertoli cells. Detailed Implementation
[0035] Example 1
[0036] Isolation, culture and purity identification of testicular Sertoli cells
[0037] Testes from healthy 3-week-old boars were collected from a Changbai boar farm in Hechuan District, Chongqing. The testes were collected aseptically and immediately placed in pre-cooled PBS buffer containing penicillin-streptomycin-amphotericidal mycoplasma, sealed, and transported to the laboratory in an ice pack for the isolation of testicular Sertoli cells. The tunica albuginea and epididymal tissue were removed aseptically in a laminar flow hood, and the testicular tissue was cut into 1 mm pieces. 3Fragmented cells were added. 0.25% trypsin-EDTA digestion solution was added, and digestion was carried out at 37°C for 20 min. The cells were then filtered through 400-mesh and 80-mesh cell sieves. The filtrate was centrifuged at 1000 rpm for 5 min, and the supernatant was discarded. Supporting cells were purified using the differential adhesion method: the cell suspension was seeded in culture dishes, and non-adherent cells were collected after incubation at 32°C for 30 min. This process was repeated twice. The purified Supporting cells were seeded in 12-well culture plates in DMEM / F12 medium containing 10% FBS, 100 U / mL penicillin, and 100 μg / mL streptomycin, and cultured in a 32°C, 5% CO2 incubator. When the testicular Supporting cells reached a density of 70-80%, the culture medium was removed, and the cells were washed three times with PBS. 300 μL of 4% paraformaldehyde was added along the wall of each well, and the cells were fixed on a shaker at room temperature for 20 min. The fixative was then removed, and the cells were washed three times with PBS. Prepare 2% BSA in PBS, add 1 mL to each well, and block at room temperature for 1 h. After blocking, remove the blocking solution and wash three times with PBS. Dilute GATA-4 primary antibody with antibody dilution buffer, add 500 μL to each well, and incubate overnight at 4°C. After incubation, remove the primary antibody and wash three times with PBS. Dilute fluorescently labeled IgG secondary antibody with PBS, add 500 μL to each well, and incubate at room temperature in the dark for 2 h. After incubation, remove the secondary antibody and wash three times with PBS. Add 20 μL of DAPI to each well, incubate at room temperature for 5 min, remove the DAPI, and wash three times with PBS. Observe and photograph under a fluorescence microscope. The results showed that the purity of the isolated and cultured primary testicular Sertoli cells reached 97±1%, which can be used for subsequent experiments (such as...). Figure 1 (As shown).
[0038] Example 2
[0039] A testicular Sertoli cell inflammation model was constructed using LPS.
[0040] Primary cultured boar testicular Sertoli cells were used at a concentration of 1×10⁻⁶. 4 Cells were seeded at a density of 10 cells / well in 96-well plates and cultured until the density reached 50-60%. Cells were divided into a control group and groups treated with different concentrations of LPS. LPS was dissolved in DMEM / F12 medium at concentration gradients (12.5, 25, 50, 100 µg / mL). After 24 h of treatment, 10 μL of CCK-8 solution was added to each well, and the cells were incubated at 37°C for 2 h. The absorbance at 450 nm was measured using a microplate reader. The results showed that LPS concentrations of 50 and 100 µg / mL significantly reduced Sertoli cell viability. Primary cultured boar testicular Sertoli cells were seeded at 1×10⁻⁶ cells / well. 5Cells were seeded at a density of 1 cell / well in 6-well plates and cultured until the density reached 60-70%. After treating cells with different concentrations of LPS for 24 h, cells were collected and lysed using RIPA lysis buffer. After centrifugation at 12000 g for 10 min, the supernatant was collected. A portion of the supernatant was used for detection using a porcine-specific IL-6 ELISA kit, and the remaining supernatant was used for Western blotting to detect the protein expression levels of inflammatory factors IL-1β and IL-18. The total protein concentration in the supernatant was detected using a BCA kit, and the concentration was adjusted to an equal volume. An SDS-PAGE gel was prepared, and an equal volume of protein sample was used for electrophoresis separation. After electrophoresis, the proteins were transferred to a PVDF membrane. After transfer, the membrane was blocked with 5% skim milk at room temperature for 2 h and washed 3 times with TBST. Primary antibodies against IL-1β and IL-18 were added, and the membrane was incubated overnight at 4°C. After incubation, the primary antibodies were removed, and the membrane was washed 3 times with TBST. IgG secondary antibody was added and incubated at room temperature for 2 h. After incubation, the secondary antibody was removed, and the cells were washed three times with TBST. Then, ECL chemiluminescence buffer was used for color development in the dark. Protein band images were acquired using a chemiluminescence imaging system, and grayscale quantitative analysis was performed using β-actin as an internal control to compare the relative expression levels of target proteins in each group. Results showed that the levels of IL-6, IL-1β, and IL-18 in Sertoli cells were significantly increased when LPS concentration was 50 µg / mL. Therefore, subsequent experiments used 50 µg / mL LPS treatment for 24 h to construct a testicular Sertoli cell inflammation model. *P<0.05, **P<0.01 (e.g., ...). Figure 2 (As shown).
[0041] Example 3
[0042] We present a method for preparing PAM (polyacrylamide) for LPS-induced testicular Sertoli cells using dielectric barrier discharge (PDD). A dielectric barrier discharge low-temperature plasma generator was used, with helium (purity ≥99.999%) as the working gas. 15 mL of DMEM / F12 culture medium containing 10% fetal bovine serum was placed in a 60 mm diameter culture dish, and the distance between the plasma generating electrode and the liquid surface was set to 10 mm. The low-temperature plasma generator was powered on, the gas flow rate was adjusted to 1.0 L / min, and exhaust was performed for 30 s. The voltage was then adjusted for discharge treatment. After treatment, the culture dish was removed, and PAM was obtained.
[0043] Steps to optimize PAM processing conditions:
[0044] (1) Different voltages of 20, 30, 40, 50, 60, 70, 80, and 90 V (corresponding to discharge powers of 0.6, 0.9, 1.4, 1.5, 1.6, 2.3, 3.0, and 3.9 W) were set, and the discharge time was fixed at 10 s. PAM at different voltages was obtained. Normal testicular Sertoli cells and LPS-induced testicular Sertoli cells were treated with PAM for 2 h. The effect of PAM on Sertoli cell viability was detected by CCK-8 assay, and the effect of PAM on the relief of Sertoli cell inflammation was determined by Western Blot. The optimal voltage was 40 V. Figure 3 (D) shows the two-dimensional scatter plot distribution of cell viability and relative expression levels of TNF-α and IL-1β. Circles in the figure mark the preferred discharge voltage parameter window of this invention. The LPS-treated group showed lower cell viability and the highest relative expression levels of TNF-α and IL-1β. Compared to the LPS-treated group, PAM within the discharge voltage range of 20–60 V increased cell viability and decreased the relative expression levels of TNF-α and IL-1β. The LPS+PAM (40 V–10 s) group fell within the preferred window; this PAM treatment, while maintaining high cell viability, resulted in the greatest reduction in the expression levels of the inflammatory factors TNF-α and IL-1β (*P<0.05, **P<0.01). Figure 3 (As shown).
[0045] (2) The voltage was kept constant at 40 V (corresponding to a discharge power of 1.4 W). Different discharge times of 10, 20, 30, 40, 50, 60, 70 and 80 s were set to obtain PAM with different discharge times. After treating normal testicular Sertoli cells and LPS-induced testicular Sertoli cells with PAM for 2 h, the effect of PAM on Sertoli cell viability was detected by CCK-8 assay and the effect of PAM on relieving Sertoli cell inflammation was determined by Western Blot. The optimal discharge time was 20 s. Figure 4 (E) shows the two-dimensional scatter plot distribution of cell viability and relative expression levels of IL-1β and IL-18. Circles in the figure mark the preferred discharge time parameter window of this invention. The LPS-treated group showed lower cell viability and higher relative expression levels of IL-1β and IL-18. Compared to the LPS-treated group, PAM with a discharge time range of 10–40 s increased cell viability and decreased the relative expression levels of IL-1β and IL-18. The LPS+PAM (40 V–20 s) group fell within the preferred window. This PAM treatment, while maintaining high cell viability, resulted in the greatest reduction in the expression levels of the inflammatory factors IL-1β and IL-18 (*P<0.05, **P<0.01). Figure 4 (As shown).
[0046] (3) Normal testicular Sertoli cells and LPS-induced testicular Sertoli cells were treated with PAM (40 V-20 s) for different treatment times of 1, 2, 3, 4, 6, 8, 10, 12 and 24 h. The effect of different PAM treatment times on Sertoli cell viability was detected by CCK-8 assay and the effect of different PAM treatment times on the relief of Sertoli cell inflammation was determined by Western Blot. The optimal treatment time of PAM (40 V-20 s) was 2 h. Figure 5 (F) shows the two-dimensional scatter plot distribution of cell viability and relative expression levels of IL-1β and IL-18. Circles in the figure mark the preferred treatment time parameter window of this invention. The LPS-treated group showed lower cell viability and the highest relative expression levels of IL-1β and IL-18. Compared to the LPS-treated group, PAM treatment within the 1–8 h time range increased cell viability and decreased the relative expression levels of IL-1β and IL-18. The LPS+PAM (2 h treatment) group fell within the preferred window. PAM (40 V-20 s) treatment for 2 h maintained the highest cell viability while significantly reducing the expression level of the inflammatory factor IL-18 (*P<0.05, **P<0.01). Figure 5 (As shown).
[0047] Example 4
[0048] The inhibitory effect of PAM and NAC on the level of inflammatory factors in LPS-induced Sertoli cells of the testis
[0049] (1) Cell viability assay (CCK-8): LPS-induced testicular Sertoli cells were treated with PAM (40 V-20 s) and NAC (5 mM) for 2 h, and cell viability was detected using CCK-8. The results showed that the cell viability of the LPS-treated group was 82.6±2.7%, which was significantly lower than that of the control group (100.0±3.5%). The cell viability of the LPS+PAM and LPS+NAC groups were 104.2±2.1% and 103.8±1.6%, respectively, which were not significantly different from the control group, but were significantly higher than those of the LPS-treated group. The cell viability of the PAM-only group was 97.6±4.2%, and the cell viability of the NAC-only group was 96.6±3.8%, which were not significantly different from the control group. *P<0.05, **P<0.01 (e.g., P<0.05, **P<0.01). Figure 6 (As shown in A).
[0050] (2) Detection of inflammatory factors (ELISA): After treating LPS-induced testicular Sertoli cells with PAM and NAC for 2 h, the cells were collected and lysed. The supernatant was used to detect porcine-specific IL-6, TNF-α and IL-1β using an ELISA kit. The results showed that the LPS-treated group had significantly higher concentrations of IL-6 (1186.6±32.1 pg / mL), TNF-α (987.5±26.3 pg / mL), and IL-1β (19.8±2.8 ng / mL) compared to the control group. In the LPS+PAM group, IL-6 concentration decreased to 728.8±36.7 pg / mL, TNF-α concentration decreased to 828.6±26.8 pg / mL, and IL-1β concentration decreased to 10.6±2.2 ng / mL. In the LPS+NAC group, IL-6 concentration decreased to 696.8±36.1 pg / mL, TNF-α concentration decreased to 816.2±26.4 pg / mL, and IL-1β concentration decreased to 11.6±2.2 ng / mL. The levels of IL-6, TNF-α, and IL-1β in the PAM-only and NAC-only treatment groups were not significantly different from those in the control group, but were significantly lower than those in the LPS-treated group. PAM showed better inhibitory effects on LPS-induced inflammatory factor levels in Sertoli cells of the testes. The levels of IL-6, TNF-α, and IL-1β in the PAM-only and NAC-only treatment groups were not significantly different from those in the control group (*P<0.05, **P<0.01). Figure 6 (As shown in BD).
[0051] (3) Detection of inflammatory cytokine proteins (Western Blot): After treating LPS-induced testicular Sertoli cells with PAM and NAC for 2 hours, total cell protein was extracted and detected by Western Blot. The results showed that the IL-18 protein level in the LPS-treated group was significantly higher than that in the control group; the IL-18 protein level in the LPS+PAM and LPS+NAC groups was significantly lower than that in the LPS-treated group, but there was no significant difference compared with the control group. This indicates that both PAM and NAC can effectively inhibit the protein expression of the inflammatory cytokine IL-18 in testicular Sertoli cells; the IL-18 protein level in the PAM-only and NAC-only treatment groups was not significantly different from that in the control group, *P<0.05, **P<0.01 (e.g., PAM-PAM-PAM-PAM-NAC ... Figure 6 E is shown.
[0052] Example 5
[0053] PAM inhibits LPS-induced increases in intracellular ROS in testicular Sertoli cells.
[0054] After treating LPS-induced testicular Sertoli cells with PAM (40 V - 20 s) for 2 h, DCFDA probe was added, and the cells were incubated at 32 °C for 20 min, followed by washing three times with PBS. Hoechst 33342 staining solution was added, and the cells were incubated at room temperature for 5 min, followed by washing three times with PBS. The cells were then detected using a fluorescence microscopy and fluorescence reader. The results showed that the ROS fluorescence signal in the control group was weak. Compared with the control group, the green fluorescence intensity and relative ROS fluorescence level of the LPS-treated group were significantly enhanced. Compared with the LPS-treated group, the green fluorescence of the LPS+PAM group was significantly weakened, and the relative ROS fluorescence level was significantly reduced, but there was no significant difference compared with the control group. Only the ROS fluorescence intensity in the PAM-treated group was not significantly different from the control group. These results indicate that PAM can significantly reduce ROS accumulation in LPS-induced testicular Sertoli cells, while PAM treatment alone has no significant effect on the basal ROS level in the cells (*P<0.05, **P<0.01). Figure 7 (As shown).
[0055] Example 6
[0056] The effect of PAM on LPS-induced inflammatory pathways in Sertoli cells of the testis
[0057] After treating LPS-induced Sertoli cells with PAM (40 V - 20 s) for 2 h, total and nuclear proteins were extracted. β-actin was used as an internal control for total protein, and Histone H3 was used as an internal control for nuclear protein. Western blotting analysis was performed. Results showed that compared with the control group, the protein levels of p-IκB / IκB, p-p65 / p65, NLRP3, and N-p65 (nuclear p65) were significantly increased in the LPS-treated group. Compared with the LPS-treated group, the protein levels of p-IκB / IκB, p-p65 / p65, NLRP3, and N-p65 were significantly decreased in the LPS+PAM group, but there was no significant difference compared with the control group. The expression of these inflammatory pathway-related proteins in the PAM-only group was not significantly different from the control group. These results indicate that PAM can effectively inhibit the activation of inflammatory pathways in LPS-induced Sertoli cells. *P<0.05, **P<0.01 (e.g., P<0.05, **P<0.01). Figure 8 (As shown).
[0058] Example 7
[0059] The effect of PAM on LPS-induced tight junction protein in Sertoli cells of the testis
[0060] After treating LPS-induced testicular Sertoli cells with PAM (40 V - 20 s) for 2 h, total cellular protein was extracted and analyzed by Western blotting. The results showed that compared with the control group, the protein levels of ZO-1, Occludin, Claudin-3, and Claudin-11 were significantly decreased in the LPS-treated group; compared with the LPS-treated group, the protein levels of ZO-1, Occludin, Claudin-3, and Claudin-11 were significantly increased in the LPS+PAM group, but there was no significant difference compared with the control group; the expression of these tight junction proteins in the PAM-only group was not significantly different from the control group. These results indicate that PAM can effectively restore LPS-induced damage to the testicular Sertoli cell barrier function (*P < 0.05, **P < 0.01). Figure 9 (As shown).
Claims
1. The use of a low-temperature plasma activating solution in the preparation of a product for inhibiting inflammatory responses in porcine testicular Sertoli cells in vitro.
2. The application according to claim 1, characterized in that: The low-temperature plasma activation solution is a plasma-activated culture medium obtained by discharging a serum-containing cell culture medium with dielectric barrier discharge low-temperature plasma under an inert working gas atmosphere.
3. The application according to claim 2, characterized in that: The inert working gas is helium, with a purity ≥ 99.999%; The serum-containing cell culture medium is DMEM / F12 medium containing 10% fetal bovine serum; During the discharge treatment, the culture medium volume was 15 mL and placed in a 60 mm diameter petri dish. The distance between the plasma generating electrode and the liquid surface was 10 mm. The helium flow rate was 1.0 L / min. The discharge treatment was carried out 30 s after exhaust.
4. The application according to claim 3, characterized in that: Under the condition of a fixed discharge time of 10 s, the discharge voltage of the discharge treatment is 20 to 60 V.
5. The application according to claim 4, characterized in that: The discharge voltage for the discharge treatment is 40 V and the discharge time is 20 s.
6. The application according to claim 1, characterized in that: The inflammatory response was a lipopolysaccharide-induced inflammatory response; The boar testicular Sertoli cells were primary boar testicular Sertoli cells that had been treated with 50 µg / mL lipopolysaccharide for 24 h to establish an inflammation model.
7. The application according to claim 6, characterized in that: The boar testicular supporting cells are primary cells with a purity ≥95% as identified by GATA-4 immunofluorescence; and / or the low-temperature plasma activation solution has a better or equivalent inhibitory effect on the level of inflammatory factors than N-acetylcysteine.
8. The application according to claim 1, characterized in that: The treatment time for boar testicular Sertoli cells with the aforementioned low-temperature plasma activation solution is 1–8 h.
9. The application according to claim 8, characterized in that: The porcine testicular supporting cells were treated with the aforementioned low-temperature plasma activation solution for 2 hours; and the cell viability recovered to a level not significantly different from the control group after treatment, and the level of lipopolysaccharide-induced inflammatory factors was significantly reduced.
10. The application according to claim 1, characterized in that: The product is used to reduce at least one of interleukin-6, tumor necrosis factor-α, interleukin-1β, and interleukin-18; and / or reduce intracellular reactive oxygen species levels; and to inhibit at least one of p-IκB / IκB, p-p65 / p65, nuclear p65, and NLRP3; and / or to restore at least one of tight junction proteins ZO-1, Occludin, Claudin-3, and Claudin-11.
